HIV-1 genotypic resistance profile of patients failing antiretroviral therapy in Paraná, Brazil

Brazilian Journal of Infectious Diseases

Volumn 14, Issue 4, 2010, Pages 360-371

  Toledo, Paula Virginia Michelon ^a   de Carvalho, Denise Siqueira ^a   Romagnoli, Luiza ^a   Marcinko, Gustavo ^a   da Cunha, Clovis Arns ^a   de Souza, Margely Nunes ^b   Brindeiro, Rodrigo ^c   de Queiroz Telles, Flávio ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b Instituto de Oncologia Do Paraná   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Antiretrovirals; Drug experienced patients; Genotype; HIV 1

Indexed keywords

PROTEINASE; RNA DIRECTED DNA POLYMERASE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; BRAZIL; DRUG TREATMENT FAILURE; FEMALE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NONHUMAN; TREATMENT DURATION; VIRUS ISOLATION; VIRUS LOAD;

EID: 78149486856     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1413-86702010000400009     Document Type: Article

References (52)

1. Okie S. Fighting HIV-lessons from Brazil. N Engl J Med 2006; 11; 354:1977-81.
2. Brazilian Program for STD/AIDS. Response + Magazine 2008: Experiences of the Brazilian AIDS Programme. Brasília, Brazil: Ministry of Health, 2008:80. [cited 2009 february 12] Available from: http://aids.gov.br/data/documents/storedDocuments
3. Vella S, Palmisano L. The Global Status of Resistance to Antiretroviral Drugs. Clin Infect Dis 2005; 41(Suppl 4):S239-46.
4. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science 1995; 267:483-9.
5. Hu DJ, Dondero TJ, Rayfield MA et al. The emerging genetic diversity of HIV. The importance of global surveillance for diagnostics, research, and prevention. JAMA 1996; 275:210-6.
6. Iversen AKN, Shafer RW, Wehrly K et al. Multidrugresistant human immunodeficiency virus type I strains resulting from combination antiretroviral therapy. J Virol 1996; 70:1086-90.
7. Ledergerber B, Egger M, Opravil M et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999; 353:863-8.
8. Shafer RW, Winters MA, Palmer S, Merigan TC. Multiple concurrent reverse transcriptase and protease mutations multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med 1998; 128:906-11.
9. Larder BA, Darby G, Richman D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243:1731-4.
10. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to Zidovudine (AZT). Science 1989; 246:1155-8.
11. Shafer RW, Rhee SY, Zioni R, Liu T, Kiuchi M. Stanford University HIV drug resistance database. [cited 2008 october 2] Available from: http://hivdb.stanford.edu/pages/asi/releaseNotes
12. Johnson VA, Brun-Vézinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: December 2008. Top HIV Med 2008; 16:138-45.
13. Hirsch MS, Günthard HF, Schapiro JM et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47:266-85.
14. Tamalet C, Fantini J, Tourres C, Yahi N. Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997- 2002) based on an analysis of over 7000 genotypes. AIDS 2003; 17:2383-8.
15. Scott P, Arnold E, Evans B et al. Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000. J Antimicrob Chemother 2004; 53:469-73.
16. Rhee SY, Liu T, Ravela J, Gonzales MJ, Shafer RW. Distribution of Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Mutation Patterns in 4,183 Persons Undergoing Genotypic Resistance Testing. Antimicrob Agents Chemother 2004; 48:3122-6.
17. Richman DD, Morton SC, Wrin T et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004; 18:1393-401.
18. Rhee SY, Fessel WJ, Zolopa AR et al. HIV-1 Protease and reversetranscriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J Infect Dis 2005; 192:456-65.
19. Napravnik S, Keys JR, Quinlivan EB, Wohl DA, Mikeal OV, Eron JJ Jr. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients. AIDS 2007; 21:825-34.
20. Tanuri A, Caridea E, Dantas MC et al. Prevalence of mutations related to HIV-1 antiretroviral resistance in Brazilian patients failing HAART. J Clin Virol 2002; 25:39-46.
21. Bahia F, Pedroso C, Netto EM, Figueiredo R, Pinto Neto L, Brites C. Evaluation of the Genotypic Pattern of HIV-1 Resistance in AIDS Patients Failing Antiretroviral Therapy. Braz Journal Infec Dis 2004; 8:281-9.
22. Cerqueira DM, Amorim RM, Silva RR, Camara GN, Brígido MM, Martins CR. Antiretroviral resistance and genetic diversity of human immunodeficiency virus type 1 isolates from the Federal District, Central Brazil. Mem Inst Oswaldo Cruz 2004; 99:877-82.
23. Couto-Fernandez JC, Silva-de-Jesus C, Veloso VG et al. Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy. Mem Inst Oswaldo Cruz 2005; 100:73-8.
24. Rodrigues R, Vazquez CMP, Colares JK et al. Antiretroviral resistance mutations in human immunodeficiency virus type 1 infected patients enrolled in genotype testing at the Central Public Health Laboratory, São Paulo, Brazil: preliminary results. Mem Inst Oswaldo Cruz 2005; 100:97-102.
25. Cavalcanti AM, Lacerda HR, Brito AM, Pereira S, Medeiros D, Oliveira S. Antiretroviral resistance in individuals presenting therapeutic failure and subtypes of the human immunodefi-ciency virus type 1 in the Northeast Region of Brazil. Mem Inst Oswaldo Cruz 2007; 102:785-92.
26. Medeiros MS, Arruda EA, Guerrant RL et al. Genotype testing and antiretroviral resistance profiles from HIV-1 patients experiencing therapeutic failure in northeast Brazil. Braz J Infect Dis 2007; 11:390-4.
27. de Sa-Filho DJ, Soares MS, Candido V et al. HIV type 1 pool gene diversity and antiretroviral drug resistance mutations in Santos, Brazil. AIDS Res Hum Retroviruses 2008; 24:347-53.
28. Shafer RW, Schapiro JM. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev 2008; 10:67-84.
29. Hirsch MS, Brun-Vézinet F, DAquila RT et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000; 283:2417-26.
30. DAquila RT, Schapiro JM, Brun-Vézinet F et al. Update on Drug Resistance Mutations in HIV-1. International AIDS Society-USA Resistance Mutations Project Panel. Top HIV Med 2001; 9:31-3.
31. DAquila RT, Schapiro JM, Brun-Vézinet F et al. Update on Drug Resistance Mutations in HIV-1. International AIDS Society-USA Resistance Mutations Project Panel. Top HIV Med 2001; 9:21-3.
32. DAquila RT, Schapiro JM, Brun-Vézinet F et al. Drug resistance mutations in HIV-1. International AIDS Society-USA Drug Resistance Mutations Group. Top HIV Med 2002; 10:11-5.
33. DAquila RT, Schapiro JM, Brun-Vézinet F et al. Drug resistance mutations in HIV-1. Top HIV Med 2002; 10:21-5.
34. DAquila RT, Schapiro JM, Brun-Vézinet F et al. Drug resistance mutations in HIV-1. Top HIV Med 2003; 11:92-6.
35. Johnson VA, Brun-Vézinet F, Clotet B et al. International AIDS Society-USA Drug Resistance Mutations Group. Drug resistance mutations in HIV-1. Top HIV Med 2003; 11:215-21.
36. Johnson VA, Brun-Vézinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med 2004; 12:119-24.
37. Johnson VA, Brun-Vézinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: 2005. Top HIV Med 2005; 13:51-7.
38. Johnson VA, Brun-Vezinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med 2005; 13:125-33.
39. Johnson VA, Brun-Vézinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 2006; 14:125-30.
40. Johnson VA, Brun-Vézinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 2007; 15:119-25.
41. Johnson VA, Brun-Vezinet F, Clotet B et al. Update of the Drug Resistance Mutations in HIV-1: Spring 2008. Top HIV Med 2008; 16:62-8.
42. Bangsberg DR, Acosta EP, Gupta R et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 2006; 20:223-31.
43. Sucupira MC, Souza IE, Costa LJ, Scheinberg MA, Diaz RS. Antiretroviral treatment failure and HIV-1 genotypic resistance in São Paulo, Brazil. Antivir Ther 2001; 6:263-4.
44. Parikh UM, Barnas DC, Faruki H, Mellors JW. Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level. J Infect Dis 2006; 194:651-60.
45. Gallego O, Ruíz L, Vallejo A, Clotet B, Leal M, Soriano V. Rate of virological treatment failure and frequencies of drug resistance genotypes among human immunodeficiency virus-positive subjects on antiretroviral therapy in Spain. J Clin Microbiol 2002; 40:3865-6.
46. Zazzi M, Corsi P, Gonnelli A et al. Evolution of the prevalence of HIV drug resistance patterns over 9 years of HAART and its relation with changes in the failing treatment regimens: an analysis of a large Italian database. XV International HIV Drug Resistance Workshop; Sitges, Spain. Antivir Ther 2006:S137.
47. Violin M, Galli A, Corvasce S et al. Study of antiretroviral resistance in treated patients with virological failure (START study): an Italian survey over the period 2003-2005. XV International HIV Drug Resistance Workshop; Sitges, Spain. Antivir Ther 2006:S132.
48. Pillay D, Green H, Matthias R et al. Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. J Infect Dis 2005; 192:967-73.
49. Costagliola D, Descamps D, Assoumou L et al. Agence Nationale de Recherches sur le SIDA et les Hepatites Virales (ANRS) AC11 Resistance Study Group. Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study. J Acquir Immune Defic Syndr 2007; 46:12-8.
50. Di Giambenedetto S, Bracciale L, Colafigli M et al. Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. Antivir Ther 2007; 12:835-9. Erratum in: Antivir Ther 2007; 12:1145.
51. Vercauteren J, Deforche K, Theys K et al. The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal. Retrovirology 2008; 5:1-8.
52. Lohse N, Obel N, Kronborg G et al. Declining prevalence of HIV-infected individuals at risk of transmitting drug-resistant HIV in Denmark during 1997-2004. Antivir Ther 2006; 11:591-600.